ArticlemSystems2025
The combination of
Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Randomized, Double-Blind, Placebo-Controlled Trial of ID-CBT5101, a TyndallizedJournal of microbiology and biotechnology · 2026Trial
- Intratumoral microbiota in tumorigenesis: A double-edged sword.Chinese medical journal · 2026Review
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review.Clinical and experimental medicine · 2026Review
- Re-arming checkpoint blockade in MSS colorectal cancer: A precision-microbiome playbook from mechanisms to clinic.Turkish journal of surgery · 2026Article
- The Role of Oral Pathobionts' Outer Membrane Vesicles in Cancer Pathology and Therapeutic Development.Cells · 2026Review
- Probiotics in colorectal cancer: mechanisms, biomarkers, and adjunct strategies.Cancer biology & medicine · 2026Review
- Review
- Synergistic effects ofmSystems · 2026Article
- Gut microecology empowers cancer immunotherapy: commensal microbiota-mediated mechanisms and translational prospects of PD-1/PD-L1 therapy.Cancer biology & medicine · 2026Review
- Integrated metabolomics and gut microbiota analyses reveal the protective effects of matrine in ulcerative colitis.Frontiers in chemistry · 2026Article
- Gut microbiota and macrophage crosstalk: implications for colitis-associated colorectal cancer.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Recent advances in the positive role ofFrontiers in immunology · 2026Review
- Gut microbial metabolites in inflammation-associated colorectal cancer: mechanisms and therapeutic implications.Frontiers in microbiology · 2026Review
- Global research trends on the gut microbiota and immunotherapy for colorectal cancer: a bibliometric analysis.Translational gastroenterology and hepatology · 2026Article
- Sodium butyrate inhibits colorectal cancer development by reducing M2 macrophage polarization and PD-L1 expression.mSystems · 2025Article
- Dynamic stability analysis of a fractional calculus-based colon cancer model with therapeutic interventions.Scientific reports · 2025Article
- Combination Therapy with Azithromycin andMicroorganisms · 2025Article
- Akkermansia muciniphila: a microbial guardian against oxidative stress-gut microbiota crosstalk and clinical prospects.Journal of translational medicine · 2025Review
- Prolonged Intestinal Ethanol Absorption and Oxidative Stress: Revisiting the Gut-Liver Axis in Alcohol-Associated Disease.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The gut microbiota is closely associated with inflammatory bowel disease (IBD) and colorectal cancer (CRC). Probiotics such as IMPORTANCE: Our study suggests that the combined administration of CB and AKK probiotics, as opposed to a single probiotic strain, holds considerable promise in preventing the advancement of IBD to CRC. This synergistic effect is attributed to the ability of this probiotic combination to more effectively modulate the gut microbiota, curb inflammatory reactions, bolster the efficacy of immunotherapeutic approaches, and optimize treatment results via fecal microbiota transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.